FS118, a tetravalent anti-LAG-3/anti-PD-L1 antibody, was evaluated in a dose-escalation and expansion clinical trial in patients with advanced/metastatic disease previously treated with anti-PD-1/PD-L1 mAbs. This evidence concerns the gene CD274 and metastatic neoplasm.